Janus Henderson Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Janus Henderson Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$675K	Buy	220,309 +82,100	+59%	+$317K	﹤0.01%	1868
2025 Q4	$565K	Hold	138,209	–	–	﹤0.01%	1970
2025 Q3	$674K	Buy	138,209 +28,481	+26%	+$150K	﹤0.01%	1864
2025 Q2	$555K	Hold	109,728	–	–	﹤0.01%	1895
2025 Q1	$638K	Buy	109,728 +26,100	+31%	+$190K	﹤0.01%	1832
2024 Q4	$565K	Hold	83,628	–	–	﹤0.01%	1975
2024 Q3	$552K	Hold	83,628	–	–	﹤0.01%	1984
2024 Q2	$626K	Buy	83,628 +21,206	+34%	+$185K	﹤0.01%	1871
2024 Q1	$621K	Buy	62,422 +25	+0%	+$278	﹤0.01%	1906
2023 Q4	$614K	Sell	62,397 -109	-0.2%	-$777	﹤0.01%	1893
2023 Q3	$478K	Buy	62,506 +96	+0.2%	+$958	﹤0.01%	1940
2023 Q2	$466K	Buy	62,410 +41,026	+192%	+$287K	﹤0.01%	2017
2023 Q1	$143K	Buy	+21,384	New	+$170K	﹤0.01%	2569
2022 Q3	–	Sell	-10,162	Closed	-$83K	–	2487
2022 Q2	$83K	Buy	+10,162	New	+$68K	﹤0.01%	2502

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Janus Henderson Group's RXRX Position: Q1 2026 in Review

Janus Henderson Group increased its Recursion Pharmaceuticals (RXRX) stake by 59% in Q1 2026, buying an estimated $317K and bringing the position to 220,309 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #1868.

Janus Henderson Group first reported a position in RXRX in Q2 2022 and has held it in 14 quarters since. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Janus Henderson Group held 220,309 shares of Recursion Pharmaceuticals worth $675K as of Q1 2026.
Janus Henderson Group bought 82,100 Recursion Pharmaceuticals shares in Q1 2026, an estimated $317K.
Recursion Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1868 holding.
Janus Henderson Group first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.